US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted A61KA61K31/7088A61P
Quick answer
US patent 12221610 (RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/7088, A61P, A61P35/00